Cognitive & Nootropic / side effects and safety / Last reviewed 2026-04-04

P21 (CNTF-Derived Peptide) Side Effects: Safety Signals and Warnings

P21 (CNTF-Derived Peptide) safety concerns are compound-specific. The main listed side effects are No significant adverse effects reported in animal studies and Potential unknown risks in humans. The main warning signals are No human trials have been conducted, Long-term effects of chronic neurogenesis stimulation are unknown, and Theoretical risk of promoting uncontrolled cell proliferation.

Read the full P21 (CNTF-Derived Peptide) guide Browse answer pages

Direct Answer

Evidence for P21 Peptide is too preliminary to support a research protocol with confidence. Published data is extremely limited - a handful of in vitro and rodent studies, with no human pharmacokinetic data or clinical trials. Of the Cognitive & Nootropic compounds in this library, cerebrolysin has vastly more clinical evidence as a starting point.

Evidence grade
Level D
Research status
Preclinical
Category
Cognitive & Nootropic
Best for
CNTF pathway mechanistic research (preclinical only)

Reported Side Effects

Warnings

Known or Plausible Interactions

Regulatory Context

Research compound only; not available for human use.

Evidence Snapshot

Evidence gradeLevel D
Research statusPreclinical
Best supported outcomesHippocampal Neurogenesis (Level D), Tau Pathology Reduction (Level D), and Spatial Memory (Level D)
Primary citation count2
Last reviewed2026-04-04

Related Guides

How to Cite This Page

ExaminePeptides. "P21 (CNTF-Derived Peptide) Side Effects: Safety Signals and Warnings." Last reviewed 2026-04-04. https://examinepeptides.com/answers/p21-peptide-side-effects-safety/

This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.